SBIR/STTR Research Award

Novel Method to Detect Pathogens for the Diagnosis of Chronic Wound Infection

Award identifier ad936f8dc6ed41e8099491041fce9d2cceb704345d09854b950c67bde1353315Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$208,311

Program and phase

SBIR · Phase I

Award year

2007

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ECI BIOTECH
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Localized infection is a frequent complication of chronic wounds that interferes with the healing process and can lead to systemic infection, limb amputation, or death. Compounding the problem is an inability of the clinician to accurately detect localized infection by clinical observation, which is still the primary diagnostic method. This is because the usual signs of infection are masked by inflammation or the patients' underlying conditions or disease. The main objective of the proposed studies is to develop and validate a new assay that will enhance the ability of clinicians to detect chronic wound infection earlier and with more accuracy. The long-term goal is to incorporate this assay into a simple, inexpensive, point-of-care device to aid in diagnosis during a patient visit. This device will help individuals with chronic wounds receive appropriate treatment sooner, allow healing to resume, relieve their pain and discomfort, and avoid the spread of infection. The diagnostic device will be based on a novel detection method for pathogenic bacteria that was developed at ECI Biotech. This method measures the activity of protein-degrading enzymes (proteases) that infection-causing pathogens release into wound fluid. Since proteases are specific toward particular sites within proteins, ECI was able to design a single target peptide that contains cleavage sites for proteases from the most common wound pathogens. The resulting assay will detect the total number of pathogens but not discern between species. In previous studies, roughly 80% of clinical isolates from chronic wounds produced proteases in vitro that cleaved this target peptide. Also, over 90% of clinical samples taken directly from infected wounds were shown to have significant protease activity toward the target peptide. This work also revealed some cross-reactivity of the target peptide with the human neutrophil elastase (HNE), a host inflammatory protease present at high levels in chronic wounds. The first goal of this proposal is to alter the amino acid sequence of the target peptide to reduce interference by HNE while maintaining sensitivity toward bacterial proteases. The next goal is to demonstrate the efficacy of the new target peptide in detecting pathogens in chronic wounds. Protease activity in samples from patients with chronic wounds occupied by 105 or more pathogenic bacteria (infected) will be compared to those that are not (non-infected). In addition to verifying that this assay can differentiate infected from non- infected chronic wounds, this study will define a cutoff activity level that distinguishes the two. The last goal of our proposal is to correlate target peptide cleavage in vitro with known quantities of purified bacterial proteases. This information will be necessary to generate standards for conversion of proteolysis activity into a simple yes-or-no readout (visible by a color change) that will be used in the diagnostic device. Overall, the studies in this proposal will improve the assay for pathogen detection and demonstrate that it is suitable to aid in the early diagnosis of wound infection. /Relevance The goal of this research is to develop a simple, inexpensive diagnostic device to help clinicians determine if a chronic wound is infected at the point-of-care. By improving the ability for early detection of chronic wound infection, patients will receive appropriate treatment sooner and at a greater frequency. This will limit the spread of local wound infection, reduce the incidence of deep or systemic wound-related infections, and restore healing.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.